Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.79
-0.27 (-1.76%)
Mar 31, 2025, 9:47 AM EDT - Market open
Takeda Pharmaceutical Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Takeda Pharmaceutical.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Takeda Pharmaceutical.
Recommendation Trends
Rating | Dec '22 | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 1 | 1 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
TD Cowen | TD Cowen | Buy Maintains $30 → $20 | Buy | Maintains | $30 → $20 | +35.27% | May 16, 2023 |
TD Cowen | TD Cowen | Buy Maintains $24 → $30 | Buy | Maintains | $24 → $30 | +102.91% | Apr 4, 2023 |
B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $20 | Hold → Strong Buy | Upgrades | $20 | +35.27% | Mar 16, 2023 |
Cowen & Co. | Cowen & Co. | Hold → Buy Upgrades $21 → $24 | Hold → Buy | Upgrades | $21 → $24 | +62.33% | Jul 19, 2022 |
Cowen & Co. | Cowen & Co. | Hold Initiates $20 | Hold | Initiates | $20 | +31.89% | Nov 1, 2019 |
Financial Forecast
Revenue This Year
4,627.60B
from 4,263.76B
Increased by 8.53%
Revenue Next Year
4,621.69B
from 4,627.60B
Decreased by -0.13%
EPS This Year
83.78
from 91.16
Decreased by -8.09%
EPS Next Year
136.59
from 83.78
Increased by 63.03%
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | 4.9T | 5.0T | 5.2T |
Avg | 4.6T | 4.6T | 4.7T |
Low | 4.3T | 4.3T | 4.2T |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 15.4% | 8.6% | 13.1% |
Avg | 8.5% | -0.1% | 1.3% |
Low | -0.0% | -6.1% | -8.2% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 101.48 | 171.81 | 243.39 |
Avg | 83.78 | 136.59 | 167.60 |
Low | 61.74 | 61.74 | 61.74 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 11.3% | 105.1% | 78.2% |
Avg | -8.1% | 63.0% | 22.7% |
Low | -32.3% | -26.3% | -54.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.